This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

QVC And Fashion Footwear Association Of New York Invest In Personalized Breast Cancer Therapy Research

WEST CHESTER, Pa., April 4, 2013 /PRNewswire/ -- QVC and the Fashion Footwear Association of New York (FFANY), building on a 19 year philanthropic relationship supporting breast cancer research, have announced a $140,000 grant to fund research at The Wistar Institute on a specific and deadly form of breast cancer called triple negative.

"The mission of the QVC-FFANY relationship is to support the most promising research with the potential to end breast cancer," said Mike George, president and CEO of QVC. "We are proud to support The Wistar Institute's work as it holds great promise for developing new treatments for breast cancer and saving women's lives." QVC addresses critical health issues for women by working with organizations, like FFANY, to invest in life-saving research.

Close to 300, 000 women are diagnosed with breast cancer each year. Of these, nearly one in four breast cancer cases is classified as triple negative. Triple negative patients have a higher rate of relapse following treatment than other breast cancer patients, and therefore, have lower overall survival rates. 

Triple negative patients have tumors that are missing three proteins found in normal cells. These proteins are critical to deciphering chemical signals, like those from hormones. The laboratory of Dario Altieri, M.D., Director of The Wistar Institute Cancer Center, set out to discover how triple negative breast cancers survive without these important proteins and, in doing so, they found a common factor. Since cells require these signals in order to grow and divide, triple negative breast cancer cells survive by using a gene that is normally "switched off" in adults: Notch-1. While the road to creating therapies is a long one, Altieri is committed to advancing research of Notch- 1 with the ultimate goal of developing new treatments for  triple negative breast cancer. 

"This funding will help us develop better, more targeted therapies against this highly aggressive form of breast cancer," Altieri said. "We are grateful to QVC and FFANY for their vision in ensuring this promising line of research moves forward."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,913.20 -1.87 -0.01%
S&P 500 1,960.85 -3.83 -0.19%
NASDAQ 4,398.2420 +2.0380 0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs